Development
AbCellera Biologics Inc.
ABCL
$4.59
$0.092.00%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -57.40% | -93.49% | -78.10% | -96.15% | -84.54% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -57.40% | -93.49% | -78.10% | -96.15% | -84.54% |
| Cost of Revenue | -77.21% | -8.89% | 14.35% | -25.85% | -237.47% |
| Gross Profit | 38.69% | -152.40% | -288.40% | -116.47% | -24.87% |
| SG&A Expenses | 21.44% | 5.66% | 10.44% | 13.63% | 6.72% |
| Depreciation & Amortization | 39.09% | 11.36% | 14.82% | 38.20% | 36.89% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.74% | -3.39% | 13.13% | -15.90% | -11.86% |
| Operating Income | -124.84% | -245.46% | -512.07% | -128.84% | -136.02% |
| Income Before Tax | -54.72% | -184.31% | -451.90% | -120.86% | -137.08% |
| Income Tax Expenses | 4.41% | -153.43% | -7,301.98% | -112.92% | -106.13% |
| Earnings from Continuing Operations | -57.73% | -207.46% | -349.93% | -123.79% | -149.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -57.73% | -207.46% | -349.93% | -123.79% | -149.86% |
| EBIT | -124.84% | -245.46% | -512.07% | -128.84% | -136.02% |
| EBITDA | -143.91% | -214.59% | -1,208.35% | -125.93% | -128.05% |
| EPS Basic | -55.56% | -205.89% | -344.12% | -123.48% | -149.13% |
| Normalized Basic EPS | -148.85% | -189.80% | -425.83% | -122.34% | -122.03% |
| EPS Diluted | -62.64% | -225.00% | -362.18% | -125.93% | -153.65% |
| Normalized Diluted EPS | -148.85% | -199.35% | -425.83% | -124.51% | -123.68% |
| Average Basic Shares Outstanding | 1.43% | 1.46% | 1.48% | 1.36% | 1.48% |
| Average Diluted Shares Outstanding | 1.43% | -8.33% | 1.48% | -7.61% | -5.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |